Ticker
    ABBV

    Price
    145.02
    Stock movement down
    -0.18 (-0.12%)
    Company name
    AbbVie Inc
    Exchange
    (NYSE
    ,
    Currency
    USD
    )
    Sector
    Healthcare >
    Drug Manufacturers-General
    Market cap
    256.46B
    Ent value
    369.93B
    Price/Sales
    4.44
    Price/Book
    16.00
    Div yield
    4.08%
    Div growth
    17.11%
    Growth years
    9
    FCF payout
    44.94%
    Trailing P/E
    19.13
    Forward P/E
    12.35
    PEG
    2.31
    EPS growth
    36.80%
    1 year return
    3.05%
    3 year return
    18.74%
    5 year return
    4.72%
    10 year return
    14.58%
    Last updated: 2023-02-06

    BUSINESS INSIGHT

    Revenues per Product Category ($M)

    Company comments

    AbbVie was created through a spinoff from Abbott Laboratories in 2013

    Humira is the world’s #1 global pharmaceutical product by a large margin

    AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

    Geographic Revenues ($M)

    DIVIDENDS

    Dividend yield - 5y

    Dividend yield data
    Dividend per share5.92
    Dividend yield4.08%
    Payout frequencyQuarterly
    Maximum yield7.32%
    Average yield4.73%
    Minimum yield3.16%
    Discount to avg yield-15.86%
    Upside potential-13.69%
    Yield as % of max yield55.78%

    Yield distribution (inverse percentile) - 5y

    Yield distribution data
    Dividend yield4.08%
    Current yield distribution71.27%
    Yield at 100% (Min)3.16%
    Yield at 90%3.71%
    Yield at 80%3.95%
    Yield at 50% (Median)4.80%
    Yield at 20%5.39%
    Yield at 10%5.77%
    Yield at 0% (Max)7.32%

    Dividend per share

    Dividend per share data
    Years of growth9 years
    CCC statusDividend Challenger
    Dividend per share5.92
    Payout frequencyQuarterly
    Ex-div date12 Jan 2023
    EPS (TTM)7.55
    EPS (1y forward)11.74
    EPS growth (5y)36.80%
    EPS growth (5y forward)8.27%

    Dividend growth

    Please create a free account or log in to access this chart
    Dividend growth data
    ABBVS&P500
    DGR MR4.96%11.59%
    DGR TTM7.53%10.54%
    DGR 3 years9.63%4.00%
    DGR 5 years17.11%5.65%
    DGR 10 years-7.37%
    DGR 15 years-5.83%
    Time since last change announced103 days
    EPS growth (5y)36.80%
    EPS growth (5y forward)8.27%

    Payout ratio

    Please create a free account or log in to access this chart
    Payout ratio data
    EPS coverageFCF coverage
    TTM73.48%44.94%
    Average--
    Forward50.43%-

    VALUATION

    Valuation Ratios

    Valuation Ratios data
    Trailing P/E19.13
    Price to OCF11.35
    Price to FCF11.70
    Price to EBITDA10.14
    EV to EBITDA14.62

    Valuation (Sales/Book Value)

    Valuation (Sales/Book Value) data
    Price to Sales4.44
    Price to Book16.00
    EV to Sales6.40

    FINANCIALS

    Per share

    Per share data
    Current share count1.77B
    EPS (TTM)7.55
    FCF per share (TTM)12.34

    Income statement

    Income statement data
    Revenue (TTM)57.82B
    Gross profit (TTM)40.26B
    Operating income (TTM)17.69B
    Net income (TTM)13.41B
    EPS (TTM)7.55
    EPS (1y forward)11.74

    Margins

    Margins data
    Gross margin (TTM)69.62%
    Operating margin (TTM)30.59%
    Profit margin (TTM)23.19%

    Balance Sheet

    Please create a free account or log in to access this chart
    Balance Sheet data
    Cash11.83B
    Net receivables10.74B
    Total current assets30.36B
    Goodwill31.73B
    Intangible assets68.72B
    Property, plant and equipment0.00
    Total assets141.32B
    Accounts payable23.50B
    Short/Current long term debt69.61B
    Total current liabilities32.71B
    Total liabilities125.30B
    Shareholder's equity16.03B
    Net tangible assets-84.46B

    Cash flow

    Please create a free account or log in to access this chart
    Cash flow data
    Operating cash flow (TTM)22.59B
    Capital expenditures (TTM)669.00M
    Free cash flow (TTM)21.92B
    Dividends paid (TTM)9.85B

    Financial returns

    Please create a free account or log in to access this chart
    Financial returns data
    Return on Equity83.65%
    Return on Assets9.49%
    Return on Invested Capital15.66%
    Cash Return on Invested Capital25.60%

    STOCK INFORMATION

    Stock chart

    Stock price data
    Open145.74
    Daily high146.33
    Daily low144.81
    Daily Volume3.77M
    All-time high174.96
    1y analyst estimate162.50
    Beta0.62
    EPS (TTM)7.55
    Dividend per share5.92
    Ex-div date12 Jan 2023
    Next earnings date9 Feb 2023

    Downside potential

    Downside potential data
    ABBVS&P500
    Current price drop from All-time high-17.11%-14.21%
    Highest price drop-48.88%-56.47%
    Date of highest drop15 Aug 20199 Mar 2009
    Avg drop from high-14.22%-11.49%
    Avg time to new high17 days13 days
    Max time to new high975 days1805 days
    COMPANY DETAILS
    ABBV (AbbVie Inc) company logo
    Marketcap
    256.46B
    Marketcap category
    Large-cap
    Description
    AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
    Employees
    50000
    Website
    https://www.abbvie.com
    Investor relations
    https://investors.abbvie.com
    SEC filings
    ABBV SEC filings
    CEO
    Richard Gonzalez
    Country
    USA
    City
    North Chicago
    Stock type
    Common stock
    CCC status
    Dividend Challenger
    Dividend Frequency
    Quarterly
    EVENTS AND PRESENTATIONS
    EventsPresentations
    UNDERSTAND THE BUSINESS
    COMPANY NEWS
    All newsPress releases
    3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
    Would you like a stock portfolio that generates enough passive income to fuel your retirement dreams? Unlike most areas of the economy, healthcare services are a top priority in good economic times a...
    February 7, 2023
    AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
    AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.
    February 6, 2023
    Abbvie plans to lift $2 billion cap on deals - WSJ
    Chief Executive Officer Richard Gonzalez said the company now has the capacity "to do more", in an interview with WSJ that was published on Monday. Abbvie is hoping to replace the loss of revenue fro...
    February 6, 2023
    AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira
    The drugmaker is turning to next-generation successors to Humira to replenish billions of dollars in sales that will be lost.
    February 6, 2023
    12 Safe Stocks to Buy For Long-Term
    In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy Acco...
    February 5, 2023
    AbbVie's (NYSE:ABBV) investors will be pleased with their favorable 80% return over the last three years
    AbbVie Inc. ( NYSE:ABBV ) shareholders have seen the share price descend 13% over the month. But don't let that...
    February 5, 2023
    2 Stocks Down More Than 6% to Buy Right Now
    In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adr...
    February 4, 2023
    3 Unstoppable Dividend Stocks to Buy in February
    Any time is a good time to buy solid dividend stocks. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). David Jagielski (Abbott Laborator...
    February 4, 2023
    AbbVie Q4 Preview: What's in Store?
    AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
    February 3, 2023
    How Revance Therapeutics, The IBD 50's No. 1 Stock, Is Taking On 'Prestige' Medical Aesthetics
    Revance Therapeutics and RVNC stock are in rarified positions after the FDA approved the company's new treatment for frown lines.
    February 3, 2023
    Next page
    Social
    Menu
    Home
    Portfolio Management
    Company Screener
    Green Investment
    About us
    Contact support
    Language EN | HU | NO | SE | DK | ES | DE | NL | FR | IT
    Disclaimer
    iO Charts assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
    © 2021 iO Charts All Rights Reserved